Literature DB >> 23275297

ADAR1 promotes malignant progenitor reprogramming in chronic myeloid leukemia.

Qingfei Jiang1, Leslie A Crews, Christian L Barrett, Hye-Jung Chun, Angela C Court, Jane M Isquith, Maria A Zipeto, Daniel J Goff, Mark Minden, Anil Sadarangani, Jessica M Rusert, Kim-Hien T Dao, Sheldon R Morris, Lawrence S B Goldstein, Marco A Marra, Kelly A Frazer, Catriona H M Jamieson.   

Abstract

The molecular etiology of human progenitor reprogramming into self-renewing leukemia stem cells (LSC) has remained elusive. Although DNA sequencing has uncovered spliceosome gene mutations that promote alternative splicing and portend leukemic transformation, isoform diversity also may be generated by RNA editing mediated by adenosine deaminase acting on RNA (ADAR) enzymes that regulate stem cell maintenance. In this study, whole-transcriptome sequencing of normal, chronic phase, and serially transplantable blast crisis chronic myeloid leukemia (CML) progenitors revealed increased IFN-γ pathway gene expression in concert with BCR-ABL amplification, enhanced expression of the IFN-responsive ADAR1 p150 isoform, and a propensity for increased adenosine-to-inosine RNA editing during CML progression. Lentiviral overexpression experiments demonstrate that ADAR1 p150 promotes expression of the myeloid transcription factor PU.1 and induces malignant reprogramming of myeloid progenitors. Moreover, enforced ADAR1 p150 expression was associated with production of a misspliced form of GSK3β implicated in LSC self-renewal. Finally, functional serial transplantation and shRNA studies demonstrate that ADAR1 knockdown impaired in vivo self-renewal capacity of blast crisis CML progenitors. Together these data provide a compelling rationale for developing ADAR1-based LSC detection and eradication strategies.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23275297      PMCID: PMC3549099          DOI: 10.1073/pnas.1213021110

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  50 in total

1.  Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML.

Authors:  Catriona H M Jamieson; Laurie E Ailles; Scott J Dylla; Manja Muijtjens; Carol Jones; James L Zehnder; Jason Gotlib; Kevin Li; Markus G Manz; Armand Keating; Charles L Sawyers; Irving L Weissman
Journal:  N Engl J Med       Date:  2004-08-12       Impact factor: 91.245

2.  Widespread inosine-containing mRNA in lymphocytes regulated by ADAR1 in response to inflammation.

Authors:  Jing-Hua Yang; Xiaoxing Luo; Yongzhan Nie; Yingjun Su; Qingchuan Zhao; Koroush Kabir; Dexin Zhang; Reuven Rabinovici
Journal:  Immunology       Date:  2003-05       Impact factor: 7.397

Review 3.  Editor meets silencer: crosstalk between RNA editing and RNA interference.

Authors:  Kazuko Nishikura
Journal:  Nat Rev Mol Cell Biol       Date:  2006-12       Impact factor: 94.444

Review 4.  Miscreant myeloproliferative disorder stem cells.

Authors:  C H M Jamieson; C F Barroga; W P Vainchenker
Journal:  Leukemia       Date:  2008-10-16       Impact factor: 11.528

5.  Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.

Authors:  Tim P Hughes; Jaspal Kaeda; Susan Branford; Zbigniew Rudzki; Andreas Hochhaus; Martee L Hensley; Insa Gathmann; Ann E Bolton; Iris C van Hoomissen; John M Goldman; Jerald P Radich
Journal:  N Engl J Med       Date:  2003-10-09       Impact factor: 91.245

6.  Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells.

Authors:  Heather G Jørgensen; Elaine K Allan; Niove E Jordanides; Joanne C Mountford; Tessa L Holyoake
Journal:  Blood       Date:  2007-01-09       Impact factor: 22.113

7.  RNA-editing-mediated exon evolution.

Authors:  Galit Lev-Maor; Rotem Sorek; Erez Y Levanon; Nurit Paz; Eli Eisenberg; Gil Ast
Journal:  Genome Biol       Date:  2007       Impact factor: 13.583

8.  Aging hematopoietic stem cells decline in function and exhibit epigenetic dysregulation.

Authors:  Stuart M Chambers; Chad A Shaw; Catherine Gatza; C Joseph Fisk; Lawrence A Donehower; Margaret A Goodell
Journal:  PLoS Biol       Date:  2007-08       Impact factor: 8.029

9.  Systematic identification of abundant A-to-I editing sites in the human transcriptome.

Authors:  Erez Y Levanon; Eli Eisenberg; Rodrigo Yelin; Sergey Nemzer; Martina Hallegger; Ronen Shemesh; Zipora Y Fligelman; Avi Shoshan; Sarah R Pollock; Dan Sztybel; Moshe Olshansky; Gideon Rechavi; Michael F Jantsch
Journal:  Nat Biotechnol       Date:  2004-07-18       Impact factor: 54.908

10.  Down-regulation of RNA editing in pediatric astrocytomas: ADAR2 editing activity inhibits cell migration and proliferation.

Authors:  Caterina Cenci; Rita Barzotti; Federica Galeano; Sandro Corbelli; Rossella Rota; Luca Massimi; Concezio Di Rocco; Mary A O'Connell; Angela Gallo
Journal:  J Biol Chem       Date:  2008-01-04       Impact factor: 5.157

View more
  81 in total

1.  PTBP1 induces ADAR1 p110 isoform expression through IRES-like dependent translation control and influences cell proliferation in gliomas.

Authors:  Bin Yang; Peishan Hu; Xihua Lin; Wei Han; Liyuan Zhu; Xiaochao Tan; Fei Ye; Guanzhou Wang; Fan Wu; Bin Yin; Zhaoshi Bao; Tao Jiang; Jiangang Yuan; Boqin Qiang; Xiaozhong Peng
Journal:  Cell Mol Life Sci       Date:  2015-06-06       Impact factor: 9.261

Review 2.  Novel insights into the biology and treatment of chronic myeloproliferative neoplasms.

Authors:  Tariq I Mughal; Tiziano Barbui; Omar Abdel-Wahab; Robert Kralovics; Catriona Jamieson; Hans-Michael Kvasnicka; Ann Mullaly; Raajit Rampal; Ruben Mesa; Jean-Jacques Kiladjian; Michael Deininger; Josef Prchal; Rüdiger Hehlmann; Giuseppe Saglio; Richard A Van Etten
Journal:  Leuk Lymphoma       Date:  2014-11-19

3.  RNA editing as an activator of self-renewal in cancer.

Authors:  Igal Germanguz; William E Lowry
Journal:  Stem Cell Investig       Date:  2016-10-31

Review 4.  The role of RNA editing by ADAR1 in prevention of innate immune sensing of self-RNA.

Authors:  Jacki E Heraud-Farlow; Carl R Walkley
Journal:  J Mol Med (Berl)       Date:  2016-04-05       Impact factor: 4.599

Review 5.  ADAR RNA editing in human disease; more to it than meets the I.

Authors:  Angela Gallo; Dragana Vukic; David Michalík; Mary A O'Connell; Liam P Keegan
Journal:  Hum Genet       Date:  2017-09-14       Impact factor: 4.132

6.  The Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human Cancers.

Authors:  Leng Han; Lixia Diao; Shuangxing Yu; Xiaoyan Xu; Jie Li; Rui Zhang; Yang Yang; Henrica M J Werner; A Karina Eterovic; Yuan Yuan; Jun Li; Nikitha Nair; Rosalba Minelli; Yiu Huen Tsang; Lydia W T Cheung; Kang Jin Jeong; Jason Roszik; Zhenlin Ju; Scott E Woodman; Yiling Lu; Kenneth L Scott; Jin Billy Li; Gordon B Mills; Han Liang
Journal:  Cancer Cell       Date:  2015-10-01       Impact factor: 31.743

7.  The RNA-editing enzyme ADAR promotes lung adenocarcinoma migration and invasion by stabilizing FAK.

Authors:  Elianna M Amin; Yuan Liu; Su Deng; Kay See Tan; Neel Chudgar; Marty W Mayo; Francisco Sanchez-Vega; Prasad S Adusumilli; Nikolaus Schultz; David R Jones
Journal:  Sci Signal       Date:  2017-09-19       Impact factor: 8.192

8.  RNA-editing enzymes ADAR1 and ADAR2 coordinately regulate the editing and expression of Ctn RNA.

Authors:  Aparna Anantharaman; Omid Gholamalamdari; Abid Khan; Je-Hyun Yoon; Michael F Jantsch; Jochen C Hartner; Myriam Gorospe; Supriya G Prasanth; Kannanganattu V Prasanth
Journal:  FEBS Lett       Date:  2017-08-30       Impact factor: 4.124

9.  RNA Splicing Modulation Selectively Impairs Leukemia Stem Cell Maintenance in Secondary Human AML.

Authors:  Leslie A Crews; Larisa Balaian; Nathaniel P Delos Santos; Heather S Leu; Angela C Court; Elisa Lazzari; Anil Sadarangani; Maria A Zipeto; James J La Clair; Reymundo Villa; Anna Kulidjian; Rainer Storb; Sheldon R Morris; Edward D Ball; Michael D Burkart; Catriona H M Jamieson
Journal:  Cell Stem Cell       Date:  2016-08-25       Impact factor: 24.633

10.  Global regulation of alternative splicing by adenosine deaminase acting on RNA (ADAR).

Authors:  Oz Solomon; Shirley Oren; Michal Safran; Naamit Deshet-Unger; Pinchas Akiva; Jasmine Jacob-Hirsch; Karen Cesarkas; Reut Kabesa; Ninette Amariglio; Ron Unger; Gideon Rechavi; Eran Eyal
Journal:  RNA       Date:  2013-03-08       Impact factor: 4.942

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.